SCHEMBL26633735

SCHEMBL26633735

CC(C)(O)CN1CCN(C(=O)C2CC3(CC(NC(=O)Nc4ccc(Cl)cc4)C3)C2)CC1

nearest known ligand 0.47

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ EPHX2 P34913 6/20 0.47
▸ ALDH1A1 P00352 3/20 0.41
▸ NPC1 O15118 1/20 0.41
▸ EPHX1 P07099 1/20 0.41
▸ CYP2C9 P11712 1/20 0.41
▸ CYP2C19 P33261 1/20 0.41
▸ RAB9A P51151 1/20 0.41
▸ SMN1; SMN2 Q16637 1/20 0.41
▸ USP30 Q70CQ3 1/20 0.40
▸ CNR1 P21554 2/20 0.40
▸ FPR1 P21462 4/20 0.39
▸ FPR2 P25090 3/20 0.39
▸ DRD2 P14416 1/20 0.39
▸ HTR2A P28223 1/20 0.39
▸ DRD3 P35462 1/20 0.39
▸ MEN1 O00255 1/20 0.38
▸ KMT2A Q03164 1/20 0.38
▸ KDM4E B2RXH2 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26764306 0.88 EPHX1 (0.46) EPHX1RAB9ASMN1; SMN2HTR2AMEN1
SCHEMBL26764199 0.88 EPHX1 (0.46) EPHX1RAB9ASMN1; SMN2HTR2AMEN1
SCHEMBL24011709 0.82 KMT2A (0.41) ALDH1A1CNR1MEN1KMT2AKDM4E
SCHEMBL26764196 0.78 MCHR1 (0.46) ALDH1A1RAB9ASMN1; SMN2
SCHEMBL26764143 0.77 SMN1; SMN2 (0.49) ALDH1A1NPC1RAB9ASMN1; SMN2MEN1
SCHEMBL24011708 0.76 EPHX1 (0.53) EPHX2ALDH1A1NPC1EPHX1RAB9A
SCHEMBL24011707 0.76 EPHX1 (0.53) EPHX2ALDH1A1NPC1EPHX1RAB9A
SCHEMBL24011500 0.76 EPHX1 (0.53) EPHX2ALDH1A1NPC1EPHX1RAB9A
SCHEMBL26633918 0.75 EPHX1 (0.44) EPHX2NPC1EPHX1RAB9ASMN1; SMN2
SCHEMBL26102875 0.71 RAB9A (0.53) EPHX2ALDH1A1NPC1RAB9ACNR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230348369-A1 NAMPT MODULATORS CYTOKINETICS, INC. 2023-11-02 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230348369-A1 NAMPT MODULATORS NAMPT, NNT, NAPRT EPHX2 4418/4885ALDH1A1 982/4885NPC1 128/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback